Cirdan Ltd secures £2.3m to expand operations in New Funding Round Led by Kernel Capital
Lisburn based Cirdan, is a global leader in digital pathology with clients in over 150 laboratories and hospitals across 20 countries and 6 continents. The Company is growing its revenues with expected 80%+ year on year growth in 2024. Cirdan has successfully secured £2.3m in new funding to expand business operations with the creation of up to 25 new jobs ahead of new contract wins. The investment was led by Kernel Capital through the Bank of Ireland Kernel Capital Growth Fund (NI). Other investors include Clarendon Fund Managers and high net worth private investors.
The funds will be used to expand their ability to grow and improve the way they onboard new customers.
The Cirdan platform, which includes specimen imaging solutions, patient and clinician apps as well as the Laboratory information system, collects critical information in a lean and expeditious way, to help transform the time taken for diagnosis and provide new insights into healthcare data. The Cirdan platform has been shown to improve efficiency and agility, provide greater control and visibility, and seamlessly integrate with digital pathology and AI.
“I would like to take this opportunity to thank our investors for their continued support. This in addition to securing several new contracts will be used to accelerate our operational expansion and deliver on our strong order book for 2023 and beyond.”
Stephen Dunniece, Director, Cirdan
“Cirdan is a company on a positive growth trajectory with an excellent product, strong team and ‘blue-chip’ clients across 6 continents. The Company is ideally placed to capitalise on the accelerated shift from traditional patient care to digital pathology which has the potential to revolutionize timely disease diagnosis leading to better and faster patient care.”
Denise Sidhu, Partner, Kernel Capital
“Cirdan are a great example of an indigenous company delivering innovative and effective solutions that are making a difference for clinicians and patients both locally and internationally. We are delighted they have benefited from investment through the Bank of Ireland Kernel Capital Growth Fund, and we look forward to seeing the business further grow and succeed.”
Niall Devlin, Head of Business Banking, Bank of Ireland UK
The Bank of Ireland Kernel Capital Growth Fund (NI) was designed to help SMEs in Northern Ireland to accelerate their growth. Invest Northern Ireland has committed £15 million of funding to this fund which is part financed by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014-2020.
-Ends-
For media enquiries contact:
Rebecca Fitton, Marketing Manager, Cirdan
T: +44 (0) 28 9266 0880 E: rfitton@cirdan.com W: www.cirdan.com
Dawn Walsh, Marketing Manager, Kernel Capital
T: +353 (0) 87 122 6807 E: dawn.walsh@kernel-capital.com W: www.kernel-capital.com
About Cirdan
Cirdan Imaging Ltd was founded on the 25th May 2010 and is a leading provider of diagnostic digital health and imaging solutions that enhance and speed up patient clinical pathways and pathology laboratory work. Headquartered in the UK, with offices in North America and Australia, Cirdan is recognised as one of the fastest-growing clinical Laboratory Information Systems (LIS) providers in the UK and Australia. The company is experiencing a period of rapid growth which is expected to continue with the addition of new innovative products and new international markets.